BATY JOSEPH W
Known title: EVP & Chief Financial OfficerCIK: 0001263696
Associated companies
Transaction History
| NATR | ▲ Buy | Grant | 23,182 | $0 | 7/21/2022 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,482 | — | 4/6/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,226 | $21K | 4/6/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 2,811 | $47K | 3/30/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,181 | $20K | 3/26/2022 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,482 | — | 3/2/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,226 | $21K | 3/2/2022 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,481 | — | 1/14/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,463 | $27K | 1/14/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,526 | $28K | 1/3/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,768 | $26K | 10/14/2021 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,481 | — | 10/14/2021 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,768 | $30K | 8/20/2021 | View on chart |
| NATR | ▲ Buy | Option Exercise | 4,481 | — | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.